Inclusion Criteria:

- Patient 18 years or older with a diagnosis of non-Hodgkin Lymphoma or chronic
lymphocytic leukemia (NHL or CLL) and one of the following:

- Progression of NHL following at least 2 prior chemotherapy regimens, (must
contain rituximab for all NHL and fludarabine for follicular NHL) defined as:

- failure to achieve partial remission (PR) with the last chemotherapy

- disease progression within 6 months following last chemotherapy

- Progression of CLL/SLL (small lymphocytic lymphoma) following at least 2 prior
chemotherapy regimens (containing purine analogs ) in stage Rai III or IV or
symptomatic disease.

- Relapsed NHL or CLL following stem cell transplantation for whom the option of
donor lymphocyte infusion is not available or clinically indicated (e.g.
recipients of autologous or umbilical cord blood [UCB] transplants).

- Available related HLA-haploidentical (human leukocyte antigen) natural killer (NK)
cell adult donor by at least Class I serologic typing

- Karnofsky performance status > 60%

- Measurable disease based on modified Response Evaluation Criteria In Solid Tumors
(RECIST)

- Have acceptable organ function as defined within 28 days of enrollment:

- Hematologic: platelets ≥ 80,000 x 10^9/L; hemoglobin ≥ 9g/dL, unsupported by
transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10^9/L, unsupported by
granulocyte-colony stimulating factor or granulocyte-macrophage
colony-stimulating factor (G-CSF or GM-CS)F for 10 days or Neulasta for 21 days
- the hematologic requirements are waived for patients with inadequate counts
due to known bone marrow involvement by lymphoma who are otherwise eligible

- Renal: glomerular filtration rate (GFR) > 50 ml/min

- Hepatic: alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3 x
upper limit of normal and total bilirubin <3 mg/dl

- Pulmonary function: >50% corrected carbon monoxide diffusing capacity (DLCO)
and Forced Expiratory Volume in the first second (FEV1)

- Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection
fraction >40%

- Off prednisone or other immunosuppressive medications for at least 3 days prior to
Day 0

- Women of childbearing potential must agree to use adequate contraception (diaphragm,
birth control pills, injections, intrauterine device [IUD], surgical sterilization,
subcutaneous implants, or abstinence, etc.) for the duration of treatment.

- Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care.

Exclusion Criteria:

- Pregnant or lactating. The agents used in this study may be teratogenic to a fetus
and there is no information on the excretion of agents into breast milk. All females
of childbearing potential must have a blood test or urine study within 2 weeks prior
to registration to rule out pregnancy. Women of childbearing age must use appropriate
contraceptive method.

- Active central nervous system (CNS) lymphoma/leukemia

- Active serious infection (pulmonary infiltrates or lesions are allowed only after the
appropriate diagnostic testing is negative for infection or appropriate therapy was
initiated for probable infection)

- Pleural effusion - large enough to be detectable on the chest x-ray

- Allergy to rituximab or IL-2

- Human immunodeficiency virus (HIV) and associated non-Hodgkins lymphoma (NHL)

- Active concurrent malignancy (except skin cancer) requiring systemic therapy in the
past 2 years

- Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder

- Positive hepatitis B surface antigen (HBsAg). If Hepatitis B core antibody (HBcAb) is
positive, Hepatitis B deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR)
will be evaluated. Positive anti HBcAb and undetectable viral load does not exclude
the patient.

- Any experimental therapy in the past 30 days

Donor Selection:

- Related donors (sibling, parent, offspring, parent or offspring of an HLA identical
sibling) ≥ age 18 years

- Able and willing to undergo lymphapheresis

- HLA-haploidentical donor/recipient match. If time permits and multiple donors are
available, preference will be given to the Killer-cell Immunoglobulin-like Receptors
(KIR) ligand mismatched donor (as predicted by HLA typing).

- HIV-1, HIV-2 negative, Human T-lymphotropic virus Type I (HTLV-1), HTLV-2 negative,
West Nile virus (WNV) negative, Hepatitis B and C negative

- Adequate organ function defined as:

- Hematologic: CBC/diff/platelet count near normal limits,

- Hepatic: ALT < 2 x upper limit of normal,

- Not pregnant or lactating

- In general good health as determined by the study physician

- Able to give informed consent